Portfolio company
LTZ Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biopharma company develops myeloid engager immunotherapies for patients with cancer and autoimmune diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Modulari-T Biosciences
This company develops modular immune receptors and delivery vehicles to create cell and gene therapies for patients with cancer and autoimmune diseases.
Candid Therapeutics
This clinical-stage biotechnology company develops T-cell engager antibodies for patients with autoimmune and inflammatory diseases.
Lycia Therapeutics
The company develops extracellular protein-degrading therapeutics for patients with autoimmune, inflammatory and allergic diseases.
T-Therapeutics
The company develops T cell receptor therapeutics and bispecific engagers for patients with cancer and autoimmune diseases.
Ouro Medicines
This biotechnology firm develops T-cell engager therapies to treat patients living with chronic immune-mediated diseases.
Bright Peak Therapeutics
This biotechnology company develops engineered cytokine immunotherapies and immunoconjugates to treat patients with cancer and autoimmune diseases.
Biotheryx
The company develops protein degrader medicines for patients with cancer and inflammatory diseases.
Laigo Bio
This company develops bispecific antibody therapies that remove disease-causing membrane proteins to treat patients with cancer and autoimmune disorders.